Sacubitril/valsartan significantly reduced cardiomyopathy risk in patients undergoing anthracycline chemotherapy, but further research is needed for broader applicability. Muvalaplin, an oral drug, ...
CHICAGO, Nov. 27, 2024 /PRNewswire/ -- Powerful Medical became the first company to win both the Best Science Startup and Overall Winner titles at the prestigious American Heart Association (AHA) ...
At this year's American Heart Association (AHA) conference, during a main event session on the topic of 'GLP-1RAs and Beyond: Incretin Analogues and a New Frontier in Cardiovascular Therapeutics', ...
Rebekah Walker, PhD, a first-time participant from the Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo, shares the offerings and opportunities at the 2024 American Heart ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results